On the other hand, FTY720 decreased sensitivity of breast cancer cells overexpressing the oncogene pp32r1 [103] and HER2 targeted therapy with lapatinib [104] potentially compromising the efficacy of FTY720 in some breast cancer clinical cotreatment regimes. This evidence concerns the gene ANP32CP and breast carcinoma.